Fusion Antibodies (FAB)

Sector:

Health Care

Index:

FTSE AIM All-Share

14.50p
   
  • Change Today:
    -0.50p
  • 52 Week High: 18.75
  • 52 Week Low: 4.00
  • Currency: UK Pounds
  • Shares Issued: 113.66m
  • Volume: 443,358
  • Market Cap: £16.48m
  • RiskGrade: 464

Fusion Antibodies expecting stronger second-half performance

By Josh White

Date: Thursday 16 Oct 2025

LONDON (ShareCast) - (Sharecast News) - Fusion Antibodies said on Thursday that it expects a stronger performance in the second half of the year after reporting first-half revenues of £0.84m, as operational efficiency improved and market sentiment began to recover.
The AIM-traded antibody discovery and engineering specialist said unaudited revenue for the six months ended 30 September was down from £1.2m a year earlier but represented a solid increase from £755,000 in the second half of the prior year.

Gross margins rose to 30% from 22%, reflecting improved efficiency and value creation.

Cash at the end of September stood at £0.25m, in line with management expectations.

Chairman Simon Douglas said the company expects an "even stronger performance in the second half, supported by our robust existing order book, promising sales opportunities pipeline and better market sentiment."

During the period, Fusion secured a key milestone with the grant of a US patent covering its 'OptiMAL' library design and method.

The company continued its collaboration with the US National Cancer Institute, which it said has demonstrated strong performance of the OptiMAL platform and led to an expanded commitment to use it in future antibody discovery projects.

Fusion also announced a series of new contract wins, including a stable cell line development project for a US-based biotech company and multiple antibody humanisation contracts with major pharmaceutical groups.

Douglas said investor and stakeholder engagement had "significantly strengthened" through presentations in London and Belfast and further development of the company's online investor hub.

He added that Fusion remained on track with its strategic goals, including the planned launch of OptiMAL in December, which "will herald a new stage in the company's development and open up new markets and revenues."

At 1537 BST, shares in Fusion Antibodies were up 5.66% at 14p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

FAB Market Data

Currency UK Pounds
Share Price 14.50p
Change Today -0.50p
% Change -3.33 %
52 Week High 18.75
52 Week Low 4.00
Volume 443,358
Shares Issued 113.66m
Market Cap £16.48m
RiskGrade 464

FAB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
55.52% below the market average55.52% below the market average55.52% below the market average55.52% below the market average55.52% below the market average
39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average
Price Trend
96.67% above the market average96.67% above the market average96.67% above the market average96.67% above the market average96.67% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income Not Available
Growth
26.15% below the market average26.15% below the market average26.15% below the market average26.15% below the market average26.15% below the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average

FAB Dividends

No dividends found

Trades for 20-Oct-2025

Time Volume / Share Price
16:29 4 @ 14.99p
16:17 4 @ 14.99p
16:16 35,000 @ 14.25p
16:15 4 @ 14.99p
16:13 200 @ 15.00p

FAB Key Personnel

Chair Simon Gordon Douglas
CEO Adrian Kinkaid

Top of Page